Claims for Patent: 5,998,209

Summary for Patent: 5,998,209

Title:	Generation of large genomic DNA deletions
Abstract:	The method of the invention provides the use of a replacement-type targeting construct to delete large fragments of genomic DNA by gene targeting. The replacement targeting construct, which may contain a selectable marker, is constructed to contain two regions of sequences which are homologous to the 5\' and 3\' flanking sequences of the targeted locus. After transfection of the targeting construct into the desired cell line, gene targeted-mediated deletions are identified by selection and further characterized. The invention is useful in any situation where one would want to create a large genomic deletion. Examples of suitable loci include MHC Class I and II antigens and immunoglobulin genes, including, for example, variable and constant region of kappa, lambda, or heavy chains.
Inventor(s):	Jokobovits; Aya (Menlo Park, CA), Tsuda; Hirohisa (Kanagawa, JP)
Assignee:	Abgenix, Inc. (Fremont, CA)
Application Number:	08/808,139
Patent Claims:	1. A method for obtaining mammalian cells comprising a genomic deletion of 55 kb, which method comprises: modifying the genome of mammalian cells containing a wild-type target locus by introducing a construct comprising two regions of sequences that are homologous to the 5' and 3' flanking sequences of said locus; identifying cells comprising said 55 kb genomic deletion by selecting cells containing a selectable marker present in said construct; and recovering mammalian cells comprising said 55 kb genomic deletion. 2. The method of claim 1 wherein said target locus is the HPRT locus. 3. The method of claim 1 wherein said target locus is an MHC Class I locus. 4. The method of claim 1 wherein said target locus is an MHC Class II locus. 5. The method of claim 1 wherein said target locus is an immunoglobulin locus. 6. The method of claim 1 wherein said mammalian cells containing a wild-type target locus are selected from the group consisting of the islets of Langerhans, adrenal medulla cells, osteoblasts, osteoclasts, epithelial cells, endothelial cells, B lymphocytes, T lymphocytes, neurons, glial cells, ganglion cells, retinal cells, keratinocytes, embryonic stem (ES) cells, liver cells, bone marrow cells, and muscle cells. 7. A mammalian cell prepared by the method of claim 1. 8. A method for preparing mammalian cells deficient in the HPRT wild-type locus, which method comprises: introducing into mammalian target cells comprising a wild-type HPRT locus a construct comprising: a first sequence homologous to the wild-type genomic sequence immediately downstream of the second exon of the HPRT wild-type locus, wherein said first sequence is congruent with a second sequence homologous to the sequence 55 kb upstream of said first sequence in the wild-type HPRT locus to produce cells comprising a deletion in the HPRT wild-type locus; identifying cells comprising said deletion by selecting cells containing a selectable marker present in said construct; and recovering said cells comprising said deletion, wherein said cells are deficient in the HPRT wild-type locus. 9. A mammalian cell prepared by the method of claim 8. 10. An ES cell prepared by the method of claim 8. 11. A mammalian cell line which comprises in its genome, a 55 kb deletion immediately upstream of the second intron of the HPRT locus. 12. A method for obtaining mammalian cells comprising a genomic deletion of about 55 kb, which method comprises: modifying the genome of mammalian cells containing a wild-type target locus by introducing a construct comprising two regions of sequences that are homologous to the 5' and 3' flanking sequences of said locus; identifying cells comprising said genomic deletion by selecting cells containing a selectable marker present in said construct; and recovering said cells comprising said genomic deletion. 13. A mammalian cell prepared by the method of claim 12. 14. An ES cell prepared by the method of claim 12. 15. The method according to claim 12, wherein said target locus is the HPRT locus. 16. The method according to claim 12, wherein said target locus is an MHC Class I locus. 17. The method according to claim 12, wherein said target locus is an MHC Class II locus. 18. The method according to claim 12, wherein said target locus is an immunoglobulin locus.

Details for Patent 5,998,209

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2015-04-21
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2015-04-21
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2015-04-21